Drug intelligence / Profile preview

CKD-381

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CKD-381 is an investigational small molecule drug developed by Chong Kun Dang Pharmaceutical for the treatment of gastroesophageal reflux disease (GERD). It is classified as a new molecular entity and has undergone several phase 1 clinical trials in healthy volunteers to assess its pharmacokinetics, pharmacodynamics, and safety. The precise mechanism of action for CKD-381 has not been disclosed or defined in public sources. The drug is administered orally in tablet form[1][2].

Brand names: EsoDuo
Other names: CKD-381CKD381CKD 381

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)CYP3A4 (Cytochrome P450 3A4)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)CYP2C19 (Cytochrome P450 2C19)

Beyond the preview

Go deeper on CKD-381.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-381.

Explore the full profile